Clinical trials: multiple sclerosis
Multiple Sclerosis, Healthy
COVID-19 Vaccine Response in Treated MS Patients
The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to…
- Trial name
- NCT05060354
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Multiple Sclerosis
Physical Activity Intervention for Individuals Newly Diagnosed With MS
The proposed study is a parallel-group randomized controlled trial (RCT) designed to establish the behavioral mechanism underlying a 16-week physical activity (PA) behavioral intervention through its effects on the…
- Trial name
- ActivNMS (NCT07731659)
- Testing
- COM-B-based Physical Activity Behavior Change Intervention
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Illinois Chicago
Scleroderma, Diffuse
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis…
- Trial name
- NCT06655896
- Testing
- rapcabtagene autoleucel, rituximab
- Where
- 93 sites in United States, Argentina and 20 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients
Multiple sclerosis is the most common autoimmune disease of the central nervous system, most ranging in age from 40-20 years of age is associated with neurons inflammation and demyelination.
- Trial name
- NCT03150966
- Testing
- Nanocurcumin
- Where
- Iran
- Volunteers
- 41 people
- Sponsor
- Tabriz University of Medical Sciences
Relapsing Multiple Sclerosis
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
Multiple Sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS), which is highly heterogeneous in terms of clinical symptoms, MS subtypes and treatment response.
- Trial name
- NCT04121065
- Testing
- Blood withdrawal
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Neuromed IRCCS
Multiple Sclerosis
Balance and Falls in Multiple Sclerosis
The study hypothesis is that for people with moderate to severe multiple sclerosis postural balance and walking improve and the risk of accidental falls are reduced after participating in a specific training intervention of 7…
- Trial name
- NCT02209467
- Testing
- Group balance training
- Where
- 7 sites in Sweden
- Volunteers
- 52 people
- Sponsor
- Örebro County Council
Multiple Sclerosis
Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods
In Multiple Sclerosis (MS) gait disorders represent one of the most disabling aspect that strongly influence patient quality of life. The improvement of walking ability is a primary goal for rehabilitation treatment.
- Trial name
- NCT02291107
- Testing
- Lokomat (Hocoma, Zurich, Switzerland), Conventional Physiotherapy
- Where
- Italy
- Volunteers
- 17 people
- Sponsor
- Habilita, Ospedale di Sarnico
Multiple Sclerosis, Parkinson Disease
Intestinal Immunity in Neurologic Disease
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
- Conditions
- Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder
- Trial name
- NCT06329453
- Testing
- Colon Tissue Biopsy
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Yale University
Multiple Sclerosis, Relapsing-Remitting
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data.
- Trial name
- NCT06897657
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Resistance Training and Amino Pyridine in Multiple Sclerosis
Prolonged-release fampridine (SR-fampridine) can improving walking capacity in approximately 40% of MS patients suffering from this by overcoming partly or total conduction block due to demyelination.
- Trial name
- RETRAP (NCT02143167)
- Testing
- SR-fampridine
- Where
- 4 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- University of Southern Denmark
Relapsing Remitting Multiple Sclerosis
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
To determine the efficacy and safety of an oral drug (BGC20-0134) in patients with relapsing remitting multiple sclerosis. Specifically, the cumulative number of new gadolinium enhancing lesions after 24 weeks of treatment with…
- Trial name
- NCT01037907
- Testing
- Pleneva TM BGC20-0134
- Where
- 35 sites in Belgium, France and 4 more
- Volunteers
- 173 people
- Sponsor
- Boston Scientific Corporation
Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with…
- Trial name
- NCT07299019
- Testing
- Orelabrutinib
- Where
- 69 sites in United States, Australia and 14 more
- Volunteers
- 990 people
- Sponsor
- Zenas BioPharma (USA), LLC
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis and the Effects of Ketogenic Diet Therapy
Multiple sclerosis (MS) is an inflammatory and immune-mediated neurological disease with multifactorial etiology. The specific etiopathogenetic mechanisms of MS are still unknown but it is clear that it results from a combination…
- Trial name
- NCT06715436
- Testing
- Mediterranean Diet, Ketogenic Diet, Control group
- Where
- Italy
- Volunteers
- 111 people
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Organic, Including Symptomatic, Mental Disorders, Substance Use
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions).
- Conditions
- Organic, Including Symptomatic, Mental Disorders, Substance Use, Schizophrenia, Mood [Affective] Disorders
- Trial name
- COMO-GMC (NCT03847753)
- Testing
- Organic Disorders, Substance Use Disorders, Schizophrenia Disorders
- Volunteers
- 5,940,299 people
- Sponsor
- University of Aarhus
Multiple Sclerosis
Safety and Dose-finding Study of DC-TAB in Healthy Subjects
The purpose of this study is to determine safety and appropriate dose of DC-TAB for selective immune tolerance induction in humans.
- Trial name
- NCT02442557
- Testing
- recombinant human alpha B-crystallin
- Where
- Netherlands
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Delta Crystallon BV
Multiple Sclerosis
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment…
- Trial name
- AmpPT (NCT06136728)
- Testing
- Dalfampridine 10 MG [Ampyra], Physical therapy, Dalfampridine plus physical therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- MGH Institute of Health Professions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Background: Multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) are disorders that affect the central nervous system (CNS). The CNS includes the brain, spinal cord, and optic nerves.
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
- Trial name
- NCT05849467
- Testing
- 89 Zr-Df-crefmirlimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis, Mitochondrial Alteration
Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) and is one of the most common neurological diseases, often leading to disability of the patients.
- Trial name
- MS-MIDY (NCT03052595)
- Testing
- Oral glucose tolerance test, Testing of autonomous nervous system function, Stroop test
- Where
- Slovakia
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Slovak Academy of Sciences
Multiple Sclerosis, RRMS
Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome measure in patients with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- OCTIMS (NCT02907281)
- Testing
- Observational
- Where
- 28 sites in United States, Australia and 10 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.